Patents by Inventor Carine Claassen-Punt

Carine Claassen-Punt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sustained release olanzapine formulations
    Patent number: 11813359
    Abstract: The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: November 14, 2023
    Assignee: Teva Pharmaceuticals International GMBH
    Inventors: Carine Claassen-Punt, Mark Alan Smith, Ling Chen, Ari Andrew Gershon
  • SUSTAINED RELEASE OLANZAPINE FORMULATIONS
    Publication number: 20220323458
    Abstract: The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described.
    Type: Application
    Filed: June 23, 2022
    Publication date: October 13, 2022
    Inventors: Mark Alan Smith, Carine Claassen-Punt
  • Sustained Release Olanzapine Formulations
    Publication number: 20210046007
    Abstract: The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described.
    Type: Application
    Filed: May 11, 2020
    Publication date: February 18, 2021
    Inventors: Carine Claassen-Punt, Mark Alan Smith, Ling Chen, Ari Andrew Gershon
  • Sustained release olanzapine formulations
    Patent number: 10646443
    Abstract: The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: May 12, 2020
    Assignee: Teva Pharmaceuticals International GmbH
    Inventors: Carine Claassen-Punt, Mark Alan Smith, Ling Chen, Ari Andrew Gershon
  • Sustained Release Olanzapine Formulations
    Publication number: 20180263911
    Abstract: The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described.
    Type: Application
    Filed: March 20, 2018
    Publication date: September 20, 2018
    Inventors: Carine Claassen-Punt, Mark Alan Smith, Ling Chen, Ari Andrew Gershon
  • SUSTAINED RELEASE OLANZAPINE FORMULATIONS
    Publication number: 20180264001
    Abstract: The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described.
    Type: Application
    Filed: May 17, 2018
    Publication date: September 20, 2018
    Inventors: Mark Alan Smith, Carine Claassen-Punt
  • SUSTAINED RELEASE OLANZAPINE FORMULATIONS
    Publication number: 20170079985
    Abstract: The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described.
    Type: Application
    Filed: September 21, 2016
    Publication date: March 23, 2017
    Inventors: Mark Alan Smith, Carine Claassen-Punt